DEF: Nutriband Inc. Sets 2026 Annual Meeting Agenda

Sentiment:

Annual Meeting Proxy Statement 19 December 2025 11:01 AM

Nutriband Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, executive compensation, and a proposed increase in authorized preferred stock.

Capital raiseSergei Glinka, a director, invested $3,300,000 in the Company's $8,400,000 private equity financing with European investors on April 19, 2024.The offering consisted of 2,100,000 units at a price of $4.00 per unit, with each unit comprising one share of common stock and a warrant to purchase two shares of common stock.The warrants have an exercise price of $6.43 and expire on April 19, 2029.The Company is proposing an amendment to increase the number of authorized preferred stock from 10,000,000 shares to 20,000,000 shares, which could be used in a future transaction, although no immediate plans for issuance are stated.

Summary

The Annual Meeting of Stockholders is scheduled for Saturday, January 24, 2026, at 10:00 A.M. (local time) in Orlando, FL.
The agenda includes the election of seven directors, ratification of Sadler, Gibb & Associates, LLC as the independent auditor for fiscal 2026, an advisory vote to approve executive compensation, an advisory vote on the frequency of future executive compensation votes, and a proposal to increase authorized preferred stock from 10,000,000 to 20,000,000 shares.
The record date for determining stockholders entitled to notice and to vote at the Annual Meeting is December 22, 2025.
As of the record date, there were 12,174,883 shares of the Company's common stock outstanding.
The Board of Directors recommends voting FOR all seven director nominees, FOR the ratification of Sadler, Gibb & Associates, LLC, FOR the advisory approval of executive compensation, FOR an annual frequency for future advisory votes on executive compensation, and FOR the amendment to increase authorized preferred stock.

Sentiment

Score: 6

Explanation: The filing is a standard proxy statement outlining routine corporate governance proposals for an annual meeting. It presents a balanced view, highlighting robust committee structures and a recent capital raise, while also disclosing conflicts of interest and minor regulatory non-compliance. No significant positive or negative operational news is presented, leading to a neutral to slightly positive sentiment.

Positives

The Board of Directors has three standing committees (Audit, Compensation, and Nominating and Corporate Governance) that are chaired and composed entirely of independent directors, meeting Nasdaq and SEC rules.
Five out of the seven current directors are independent, enhancing independent oversight.
The Audit Committee actively oversees financial reporting, internal controls, and the independent auditors' performance, with Mark Hamilton qualifying as an audit committee financial expert.
The Compensation Committee oversees executive compensation and general compensation policies, ensuring alignment with company goals.
The Nominating and Corporate Governance Committee identifies qualified nominees, oversees internal governance, and maintains a management succession plan.
No compensation committee interlocks or insider participation exists, promoting independent decision-making.
The Company has entered into indemnification agreements with its directors and executive officers, providing protection to key personnel.
Sergei Glinka, a director, demonstrated confidence in the Company by investing $3,300,000 in a private equity financing round in April 2024.

Negatives

Certain conflicts of interest exist and may continue to exist between the Company and its officers and directors due to their other business interests.
The Company has not established specific policies or procedures for the resolution of current or potential conflicts of interest.
Dr. Smith, Dr. Patrick, Mr. Bujoreanu, and Ms. Gram have not filed their Form 3 reports, indicating non-compliance with Section 16(a) of the Securities Exchange Act of 1934.
The proposed increase in authorized preferred stock from 10,000,000 to 20,000,000 shares, while not immediately planned for issuance, could lead to future dilution if utilized.

Risks

Conflicts of interest may arise between the Company and its officers and directors due to their other business interests, and there are no established policies for their resolution.
Non-compliance with Section 16(a) of the Exchange Act by certain officers and directors regarding Form 3 filings could lead to regulatory scrutiny.
The increase in authorized preferred stock, if issued, could result in dilution for existing common stockholders.
Indemnification obligations to directors and executive officers are not limited in amount or duration, and potential liabilities cannot be determined until a lawsuit is filed, posing an unknown financial risk.
Forward-looking statements are subject to risks and uncertainties, including global conflicts (Russia-Ukraine), economic and currency conditions, market demand, pricing, intellectual property protection, competitive and technological factors, and inflation, as detailed in the Company's Annual Report on Form 10-K.

Future Outlook

The Company expects its next annual meeting to occur in January 2027. While the Board recommends annual advisory votes on executive compensation, it may decide to conduct them less frequently in the future based on stockholder discussions and changes to compensation programs. The Company is seeking approval to increase authorized preferred stock but has no immediate plans for further issuance of Series A Convertible Preferred Stock or newly authorized undesignated shares, though these could be used in future, currently unforeseen transactions. Future bonuses will be tied to performance criteria directly related to executive responsibilities, with more defined bonus programs potentially established as the company grows.

Management Comments

"YOUR VOTE IS IMPORTANT. It is important that as many shares as possible be represented at the annual meeting."
"The Board of Directors knows of no other matters to be presented for shareholder action at the Annual Meeting."
"The Board of Directors and the Compensation Committee value the opinions of our stockholders and to the extent there is any significant vote against the named executive officers compensation as disclosed in this Proxy Statement, we will consider our stockholders concerns and the Compensation Committee will evaluate whether any actions are necessary to address those concerns."
"We believe that annual say-on-pay votes are generally considered a corporate governance best practice and align with the voting policies and recommendations of leading institutional investors and proxy advisors."
"We are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change in control of our company."
"We have approved and are seeking the approval for an additional 10,000,000 shares of undesignated preferred stock have not planned any for these additional shares and do not expect any further issiamce or issuances of these unissued shares of Series A Cmvertible Preferred Stock or of any newly authorized undesignated shares of Preferred Stock, although the additional undesignated shares could be used in a future transaction of which we are not now aware at this tune."

Industry Context

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Accounting Officer	NA	Gerald Goodman	July 31, 2018	Appointed to role
Chief Financial Officer	NA	Gerald Goodman	November 12, 2020	Elected to role
President	NA	Serguei Melnik	October 8, 2021	Elected by the Board
Director	NA	Sergei Glinka	May 15, 2024	Joined Board after private offshore financing investment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Share Capital Increase Proposal	Proposal to amend the Articles of Incorporation to authorize an increase in preferred stock from 10,000,000 shares to 20,000,000 shares.	Upon stockholder approval at January 24, 2026 Annual Meeting	Provides greater flexibility for future capital raises or strategic transactions, but introduces potential for dilution if shares are issued.
Regulatory Compliance Issue	Dr. Smith, Dr. Patrick, Mr. Bujoreanu, and Ms. Gram have not filed their Form 3 reports as required by Section 16(a) of the Securities Exchange Act of 1934.	NA	Indicates a lapse in regulatory compliance for certain insiders, potentially raising concerns about transparency and adherence to SEC reporting requirements.

Related Party Transactions

Sergei Glinka, a director, invested $3,300,000 in the Company's $8,400,000 private equity financing on April 19, 2024, receiving 825,000 shares of common stock and warrants to purchase 1,650,000 shares of common stock.
Stock options were issued to various officers and directors on March 20, 2024, and January 23, 2025, with specified exercise prices and expiration dates.
Employment agreements with CEO Gareth Sheridan and President Serguei Melnik include annual salaries, performance bonuses, severance packages, and gross-up reimbursement for excise taxes.
Disclosed conflicts of interest exist between the Company and its officers and directors due to their other business interests.

Stakeholder Impact

Shareholders will vote on key corporate governance matters, including director elections, auditor ratification, executive compensation, and a significant increase in authorized preferred stock, which could impact future ownership structure.
Employees, particularly executive officers, are directly impacted by the executive compensation proposals and the potential for future bonus programs tied to performance.
Company management and directors are subject to re-election and their compensation is under review, with indemnification agreements providing protection.
Auditors, specifically Sadler, Gibb & Associates, LLC, are proposed for ratification for fiscal 2026, impacting their ongoing relationship with the Company.

Next Steps

Stockholders are encouraged to vote on the proposals for director elections, auditor ratification, executive compensation, frequency of executive compensation votes, and the increase in authorized preferred stock at the Annual Meeting on January 24, 2026.
The Board and Compensation Committee will consider stockholder concerns if there is a significant vote against executive compensation.
The Board may decide to vary the frequency of advisory votes on executive compensation in the future based on discussions with stockholders and changes to compensation programs.
Stockholder proposals for the fiscal 2027 Annual Meeting must be received by October 1, 2026, to be eligible for inclusion in the Company's proxy statement.
Stockholder proposals not for inclusion in the proxy statement for the 2027 Annual Meeting must be noticed by October [blank], 2026.

Key Dates

Date	Description
June 1995	Serguei Melnik began practicing law in Moldova, including a role in the Department of Foreign Affairs, JSC Bank Inteprinzbanca.
August 1999	Radu Bujoreanu began working as a consular officer at the Embassy of the Republic of Moldova to the United States.
February 2003	Serguei Melnik became Chief Operations Officer and a Board member of Asconi Corporation.
December 2002	Radu Bujoreanu became owner and executive director of Consular Assistance, Inc.
2011	Alan Smith co-founded 4P Therapeutics.
2012	Gareth Sheridan founded Nutriband Ltd. (Irish company) and received a B.Sc. in Business and Management from Dublin Institute of Technology.
2014	Gareth Sheridan was named Ireland's Young Entrepreneur of the Year.
2014	Gerald Goodman began practicing with his own firm, Gerald Goodman CPA P.C.
January 2016	Nutriband Inc. acquired Nutriband Ltd., and Gareth Sheridan became CEO and director. Serguei Melnik served as CFO and director.
July 31, 2018	Gerald Goodman became Chief Accounting Officer.
2018	Nutriband acquired 4P Therapeutics.
June 2019	Radu Bujoreanu became a director.
2019	Sergei Glinka became Commercial Manager of TG Biochemicals Limited and a shareholder/board member of GST Investments O.
November 12, 2020	Gerald Goodman was elected Chief Financial Officer.
October 8, 2021	Serguei Melnik was elected President.
January 21, 2022	Irina Gram was elected as a director.
February 1, 2022	Three-year employment agreements with Gareth Sheridan and Serguei Melnik became effective.
July 31, 2022	Gareth Sheridan and Serguei Melnik mutually agreed to reduce their annual salary to $150,000.
March 20, 2024	Stock options were issued to certain officers and directors with exercise prices of $2.62 or $2.37 per share, expiring March 20, 2027.
April 19, 2024	Sergei Glinka invested $3,300,000 in the Company's $8,400,000 private equity financing with European investors.
May 15, 2024	Sergei Glinka joined the Board of Directors.
September 19, 2024	Vitalie Botgros's Schedule 13-D filing was made.
January 23, 2025	Stock options were issued to certain officers and directors with exercise prices of $8.07 or $7.34 per share, expiring January 23, 2028.
January 31, 2025	End of the fiscal year for which audited financial statements were reviewed by the Audit Committee.
April 28, 2025	The Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2025, was filed with the SEC.
July 9, 2025	The Board of Directors approved an amendment to the Articles of Incorporation authorizing Series A Convertible Preferred Stock.
December 17, 2025	Date for which beneficial ownership information is provided in the proxy statement.
December 19, 2025	Date of Gareth Sheridan's (CEO) signature on the proxy statement.
December 22, 2025	Record date for determining stockholders entitled to notice of and to vote at the Annual Meeting.
December 31, 2025	Proxy materials were mailed to shareholders.
January 24, 2026	Date of the Annual Meeting of Stockholders.
January 31, 2026	End of the fiscal year for which Sadler, Gibb & Associates, LLC is proposed as the independent auditor.
October 1, 2026	Deadline for stockholder proposals for the fiscal 2027 Annual Meeting to be eligible for inclusion in the Company's proxy statement.
October , 2026	Deadline for stockholder proposals not submitted for inclusion in the proxy statement but sought to be presented directly at the 2027 Annual Meeting.
January 2027	Expected date of the Company's next annual meeting.
March 20, 2027	Expiration date for stock options granted on March 20, 2024.
January 23, 2028	Expiration date for stock options granted on January 23, 2025.
April 19, 2029	Expiration date for warrants issued in the private equity financing completed on April 19, 2024.

Recommendation

hold

This filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance and administrative matters such as director elections, auditor ratification, and executive compensation. While it includes a proposal to increase authorized preferred stock, the Company explicitly states no immediate plans for issuance, mitigating immediate dilution concerns. The disclosed conflicts of interest and Section 16(a) non-compliance for some individuals are minor governance issues that do not fundamentally alter the investment thesis. The filing does not contain new operational or financial results that would warrant a change in investment recommendation, thus a 'hold' position is appropriate for a seasoned investor.

Keywords

Nutriband, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Executive Compensation, Auditor Ratification, Preferred Stock, Capital Raise, Stock Options, SEC Filing, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.